Discover
PHGE
BiomX Inc.
0.32
1700 x undefined
200 x 0.33
bid
ask
-
0.03
8.19%
950 @ 06:17 AM
0.32 +0.00 (1.16%)
| Ytd | -82.93% | |
| 1y | -96.18% |
0.32
day range
0.34
0.30
52 week range
14.71
| Open | 0.33 | Prev Close | 0.35 | Low | 0.32 | High | 0.34 | Mkt Cap | 3.77M |
| Vol | 875.69K | Avg Vol | 6.46M | EPS | -23.30 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.32 | Short Ratio | 0.74 | Inst. Own | 52.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 0.75 | 200-d Avg | 4.54 | 1yr Est | 7.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.6 | -0.97 | -0.37 | -61.67% |
| 2024-08-14 | 2024-06 | -1.2 | 0.7 | 1.9 | 158.33% |
| 2024-08-14 | 2024-06 | -1.2 | N/A | N/A | N/A |
| 2024-05-20 | 2024-03 | -0.7 | N/A | N/A | N/A |
| 2024-05-20 | 2024-03 | -0.7 | -1.5 | -0.8 | -114.29% |
| 2024-04-03 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-28 | Laidlaw & Co. | Upgrade | Buy | |
| 2024-05-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-15 | BASSAN MARAV | Officer | 31.75K | Stock Award(Grant) |
| 2024-05-14 | CYSTIC FIBROSIS FOUNDATION | Beneficial Owner of more than 10% of a Class of Security | 9.33M | Conversion of Exercise of derivative security |
| 2024-07-14 | FLYNN JAMES E | Director | 0.00 | Conversion of Exercise of derivative security |
| 2024-05-14 | ORBIMED ISRAEL BIOFUND GP, L. P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-09-15 | ORON ASSAF | Officer | 25.80K | Stock Award(Grant) |
| 2024-09-15 | SOLOMON JONATHAN EITAN | Chief Executive Officer | 53.06K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Orbimed Advisors LLC. | 1.79M | 983.27K | 9.84% |
| 2024-09-29 | Deerfield Management Company, L.P. (Series C) | 1.79M | 983.19K | 9.83% |
| 2024-09-29 | Nantahala Capital Management, LLC | 1.73M | 951.83K | 9.52% |
| 2024-09-29 | Ikarian Capital, LLC | 893.00K | 491.15K | 4.91% |
| 2024-09-29 | AIGH Capital Management LLC | 865.40K | 475.97K | 4.76% |
| 2024-09-29 | Heights Capital Management, Inc | 589.03K | 323.96K | 3.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2023-12-30 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 49.50K | 27.23K | 0.07% |
Split
| Split | Date |
|---|---|
| 1 : 19 | 2025-11-25 |
| 1 : 10 | 2024-08-26 |